A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Glioblastoma Multiforme

Interventions

DRUG

BEY1107

Administer twice daily, PO, 4-week continuous dose.

COMBINATION_PRODUCT

Temozolomide

Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

BeyondBio Inc.

INDUSTRY